Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.
Dana HorákováAaron BosterAntonio BertolottoMark S FreedmanIsabel FirminoSteven J CavalierAlan K JacobsKarthinathan ThangaveluNadia DaizadehElizabeth M PooleDarren P BakerDavid H MargolinTjalf Ziemssennull nullPublished in: Multiple sclerosis journal - experimental, translational and clinical (2020)
The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting further study of the role alemtuzumab may play in reducing risk of secondary progression.ClinicalTrials.gov identifiers: NCT00530348, NCT00548405, NCT00930553.